BPC-157 dosage calculator: the mcg to syringe units tool

Three conversions stacked on top of each other

Milligrams to micrograms: the vial field takes milligrams, the amount field takes micrograms, and one milligram is 1,000mcg. A misplaced decimal here is a thousandfold error, not a rounding one.

Mass to concentration: vial milligrams divided by water milliliters gives mg per mL, and multiplying by a thousand restates the same liquid as mcg per mL, which is the unit the rest of the arithmetic wants.

Concentration to a mark: mcg per mL divided by the barrel's units per mL gives the micrograms inside one unit. On a U-100 barrel that is the concentration divided by 100, because one unit is 0.01mL.

What the stack means in practice: a vial holding 5mg is holding 5,000mcg, and where a given amount of that lands on a barrel is decided by the water first and then by which scale the barrel uses. The converter does the three steps in order and shows its working at each one.

Is there a label concentration to check a vial against?

What FDA said in July 2026: in the briefing document prepared for the Pharmacy Compounding Advisory Committee meeting of 23 and 24 July 2026, the agency states that there is no applicable United States Pharmacopeia or National Formulary drug substance monograph for BPC-157 free base or its acetate form, and that neither is a component of an FDA-approved drug.

What the same document says about naming: BPC-157 is a common name rather than a United States Adopted Name, and the agency reports having encountered multiple salts and derivatives, including different active moieties, sold commercially under that one common name.

Why that lands on the arithmetic: the free base and the acetate are treated as distinct active pharmaceutical ingredients with distinct chemical structures. A milligram of weighed acetate salt and a milligram of weighed free base do not contain the same amount of peptide, so a milligram figure only settles the arithmetic once it is clear which of the two it describes.

What the certificates usually cover: the same document reports that most certificates of analysis found for BPC-157 free base contain purity testing results only, with no information on impurity limits. Purity is a percentage of what is there, and says nothing about how much of it there is.

Where the agency landed: after weighing its criteria, FDA wrote that the balance weighs against placing either substance on the list of bulk drug substances usable in compounding under section 503A. The World Anti-Doping Agency separately lists BPC-157 as prohibited under S0, unapproved substances.

Where the committee landed, which is not the same thing: the advisory committee was asked whether the free base and the acetate should go on that list, and on 23 July 2026 it voted yes. The tally reported by the Associated Press and NBC News was 8 in favor, 6 against and 1 abstention. A committee recommendation is not a rule and not an approval, and as of 29 July 2026 FDA has published no minutes and no decision, so nothing has changed about what a label would have to say.

One worked example in micrograms

The setup: a 5mg vial and 2.5mL of bacteriostatic water gives 2mg per mL, which restated is 2,000mcg per mL. One U-100 mark then holds 20mcg.

Where that number comes from: 2,000mcg per mL is also the subcutaneous strength the withdrawn compounding nominations proposed, per the same FDA briefing document, which makes it a convenient figure to work through rather than an invented one.

What the table is not: a schedule, a ladder, or a set of amounts anyone is suggesting. They are five round microgram figures picked to make the division readable, and the converter will run any others brought to it.

How many units is 1mg of BPC-157?

One milligram is 1,000mcg, and where those micrograms land depends on the water and then on the scale. At 2,000mcg per mL, which is a 5mg vial in 2.5mL, 1mg occupies 0.5mL and reads as 50 units on a U-100 barrel. The same vial dissolved in 1mL instead gives 5,000mcg per mL, so 1mg sits at 20 units. The vial did not change, the compound did not change, and the mark moved by a factor of two and a half.

What does mcg mean on a BPC-157 vial?

Nothing on its own. A microgram is one thousandth of a milligram, so a 5mg vial holds 5,000mcg and a 10mg vial holds 10,000mcg, and the letters only matter once a number is attached to them. The confusion is worth naming because the error mode is not subtle: mistaking mcg for mg moves an answer by three decimal places in one direction or the other. Whether the wrong answer looks obviously wrong depends on where the correct one sat, so a result that lands off the barrel entirely is one signal, and a plausible-looking result is not a clearance.

Does the acetate form change the milligram math?

It changes what the milligrams are made of: FDA treats BPC-157 free base and BPC-157 acetate as distinct active pharmaceutical ingredients, each with its own chemical structure and its own physical and chemical properties.

A salt carries extra mass: in an acetate salt part of the weighed material is acetate rather than peptide, so a figure describing weighed salt and a figure describing net peptide are not the same number. Which of the two a given label states is not something this page or the tool can determine, and FDA's document reports that most certificates of analysis found for the free base carry purity results only.

What the arithmetic can and cannot see: the converter divides the number typed into the vial field. It has no way to know which substance produced that number, which is why the label and the certificate of analysis matter more than the tool does.

Why does the tool insist on a syringe scale?

Because a unit is a volume mark, and the two common scales divide a milliliter differently. U-100 splits it into 100 units of 0.01mL and U-40 splits it into 40 units of 0.025mL, so the same number on a U-40 barrel holds 2.5x the liquid. At one fixed concentration that is 2.5 times the micrograms, and the error is in the reading rather than in the number, so it survives being double-checked against the count itself. The converter therefore prints no per-unit value at all until a scale has been chosen.

The rest of the vial math

What sits next to it: four more pages from the dose-math library, each holding a different piece of the same arithmetic.

• mcg vs mg: the thousandfold step this page leans on, taken apart on its own terms.
• What is a unit: where the barrel mark came from and what it can and cannot report.
• Reconstitution calculator: vial and water to concentration, then a draw volume for any figure brought to it.
• What is bacteriostatic water: the diluent in the second field, and what its own label says about itself.
• The Decadewise briefing: one tool or one label read like this, in your inbox once a week.

How this page is sourced

The regulatory statements come from the source document: FDA's own briefing package for the July 2026 advisory committee meeting, not from a summary or a vendor page. Where the page states a finding in its own words it is a close paraphrase of that document rather than a quotation.

The clinical statements come from the abstracts and from the regulator's catalogue: one review and three pilot reports, each cited below with its identifier, plus the FDA appendix that lists all five human studies and the registry record behind the trial search.

What is missing is a regimen, not the amounts: the review below states that no validated dosing regimen exists, so this page proposes none. The milligram figures in the study section are what those named reports administered, reported as their record. Every number in the worked example is arithmetic on the vial and water stated beside it.

What changed on 29 July 2026, and why: this page said the human record was three uncontrolled pilots with no completed phase 2. That came from the cited review, and we had not checked it against the regulator's file. FDA's appendix of previous human experience lists five studies and two randomized placebo-controlled ones, so the section was rewritten around the FDA document and the review is now quoted only for what it can support. The vote taken at the July meeting was added at the same time. No arithmetic on the page changed.

What we cut on 2 August 2026, stated plainly: this page carried registry record NCT07437547 as a recruiting phase 2 of subcutaneous BPC-157, with 120 participants planned, in the answer box, in the evidence section and in the reference list. All three are gone. The sponsor named on that record has eight studies on ClinicalTrials.gov, two of which describe themselves as specimens in their own summaries, one opening "This fictional study is an example of a ClinicalTrials.gov-style record". All eight share one facility and one pair of contact addresses, on an email domain that does not match the sponsor's name, and one carries a study identifier prefixed EX. We cannot show that NCT07437547 is a fabrication and we are not saying it is. We are saying it cannot carry the claim we hung on it, and our rule is that such a claim is cut rather than softened. NCT02637284 replaces it in the reference list as the only other record the registry returns for this compound. No arithmetic on this page changed.

The standard: the full sourcing and citation-verification standard for this site, including who checks a page before it ships, lives on the methodology page.

Last reviewed: 28 July 2026.

1. 1

   U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, 23 to 24 July 2026: Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 free base and BPC-157 acetate), introduction, evaluation criteria and conclusion sections, plus Appendix 1 on previous human experience, which is the source of the five-study record and of the enema-study figures. Retrieved 29 July 2026, HTTP 200. Briefing document. The voting questions are in the separate meeting questions document, retrieved the same day, HTTP 200.

2. 2

   Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625. PMID 42198317.

3. 3

   Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435.

4. 4

   Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560.

5. 5

   Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143.

6. 6

   ClinicalTrials.gov. PCO-02, Safety and Pharmacokinetics Trial. Identifier NCT02637284, phase 1, randomized, quadruple-masked, 42 participants estimated, oral tablets whose active ingredient the official title gives as BPC-157. First posted 22 December 2015, last updated 17 December 2015, overall status unknown, no results posted. Record and the two searches behind the trial paragraph above, for BPC-157 and for BPC 157, pulled through the registry API on 2 August 2026, HTTP 200, two records returned on each. Registry record.

7. 7

   U.S. Anti-Doping Agency. BPC-157: Experimental Peptide Prohibited. usada.org. Agency page.

8. 8

   News reporting of the committee vote, not an FDA record. Perrone M. FDA reviews BPC-157, TB-500 and other peptides favored by RFK Jr. Associated Press, 23 July 2026. apnews.com. NBC News, 23 July 2026, reporting 8 yes, 6 no and 1 abstention on BPC-157, KPV and TB-500. nbcnews.com. Both retrieved 29 July 2026, HTTP 200.